Camostat Mesilate

DRUG11 trials

Conditions

COVIDCOVID-19Chronic Kidney Disease with proteinuriaCorona Virus InfectionCoronavirus InfectionCovid19DiabetesHypertension

Phase 1

The Impact of Camostat Mesilate on COVID-19 Infection

CompletedNCT04321096

University of AarhusCorona Virus Infection

Start: 2020-04-04End: 2023-05-01Updated: 2025-04-18

Camostat With Bicalutamide for COVID-19

TerminatedNCT04652765

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCoronavirus Infection, Covid19, SARS-CoV Infection

Start: 2021-02-03End: 2021-09-15Updated: 2023-10-06

Phase 2

Camostat Mesylate in COVID-19 Outpatients

CompletedNCT04353284

Yale UniversityCOVID-19

Start: 2020-06-09End: 2021-04-22Updated: 2022-03-24

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

TerminatedNCT04374019

Susanne ArnoldCOVID, Sars-CoV2

Start: 2020-05-01End: 2022-01-12Updated: 2022-01-20

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

CompletedNCT04470544

Alan BryceSevere Acute Respiratory Syndrome

Start: 2020-07-28End: 2022-01-20Updated: 2024-11-12

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

CompletedNCT04524663

Stanford UniversityCovid19

Start: 2020-12-19End: 2021-05-15Updated: 2022-06-10

Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

TerminatedNCT04530617

Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranCovid19, Diabetes, Hypertension +1

Start: 2020-10-05End: 2021-06-10Updated: 2021-06-21

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

CompletedNCT04583592

Sagent Pharmaceuticals Inc.COVID-19

Start: 2020-11-09End: 2021-03-31Updated: 2022-01-18

Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

CompletedNCT04681430

Heinrich-Heine University, DuesseldorfCorona Virus Infection, SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Infection +1

Start: 2021-01-08End: 2021-10-29Updated: 2022-02-10

Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid).

RecruitingCTIS2023-508516-34-00

Odense University HospitalChronic Kidney Disease with proteinuria

Start: 2024-10-30Target: 40Updated: 2025-12-22

Phase 4

Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19

WithdrawnNCT04338906

Heinrich-Heine University, DuesseldorfCOVID

Start: 2020-05-31End: 2021-12-31Updated: 2020-12-21

Related Papers

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.

2022-04-125 citations

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.

2021-05-176 citations

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

2021-04-22153 citations